Supplementary File: Efficacy and safety of lebrikizumab in adolescents with atopic dermatitis over 24 weeks: An analysis from the BIOREP registry

Name: Supplementary File: Efficacy and safety of lebrikizumab in adolescents with atopic dermatitis over 24 weeks: An analysis from the BIOREP registry
Creator: Filip Rob
Published: 2026-01-26T11:28:37.543Z
Keywords: Adolescent, Biologicals, Atopic Dermatitis

Rob, Filip; Pinková, Blanka; Gkalpakioti, Petra; Bartoňová, Jiřina; Horažďovský, Jiří; Říčař, Jan; Hercogová, Jana; Sokolová, Kristýna

doi:10.17632/vgt9vjj99m.1

Supplementary File: Efficacy and safety of lebrikizumab in adolescents with atopic dermatitis over 24 weeks: An analysis from the BIOREP registry

Published: 26 January 2026| Version 1 | DOI: 10.17632/vgt9vjj99m.1

Contributors:

Filip Rob, Blanka Pinková, Petra Gkalpakioti,

, Jiří Horažďovský,

,

Description

Figure S1. Response to lebrikizumab treatment in adolescents naive to targeted therapy and in those with prior targeted-therapy failure at 16 and 24 weeks

Supplementary File: Efficacy and safety of lebrikizumab in adolescents with atopic dermatitis over 24 weeks: An analysis from the BIOREP registry

Description

Files

Categories

Licence